GROK8 Mar 2026 19:43
From GROK: Just as a reminder
CIZ1B (often written as CIZ1b in scientific literature) is a cancer biomarker primarily associated with early detection of lung cancer.It refers to a specific variant (or splice isoform) of the protein produced by the CIZ1 gene (CDKN1A-interacting zinc finger protein 1). In lung cancer patients — particularly non-small cell lung cancer (NSCLC) — this variant is released by tumor cells into the bloodstream, where it can bind to fibrinogen and be detected via a simple blood test.Key points about CIZ1B as a biomarker:Developed and commercialized primarily by Cizzle Biotechnology (UK-based) and their partner Cizzle Bio in the US.
The test aims for early-stage detection (especially Stage I), with reported performance including 95% sensitivity for Stage I and high negative predictive value (96%).
It shows strong discriminatory power in high-risk groups (e.g., heavy smokers or those with lung nodules), with ROC AUC values often >0.9 in studies — meaning very good accuracy in distinguishing cancer cases from non-cancer.
Intended as a minimally invasive, low-cost blood test to complement or improve upon current screening methods like low-dose CT scans, which have low uptake due to access, cost, radiation concerns, and false positives.
By March 2026, it's advancing toward broader commercial availability in the US (via CLIA labs), with ongoing clinical evaluations (e.g., partnerships/trials with centers like Moffitt Cancer Center) and economic modeling showing potential to reduce healthcare costs while saving lives through earlier intervention.
It's not a genetic mutation like EGFR or ALK — it's a circulating protein biomarker useful for screening/diagnosis rather than targeted therapy selection.If you're asking about something else (e.g. a typo, code, username, product code, etc.), feel free to give more context!
Sign In
Follow the stocks
